P. Latasha Ea

Biography

Director, Center for Protein Therapeutics with research focusing on the utilization of pharmacokinetic and pharmacodynamic analyses and mathematical modeling to guide the discovery and development of new immunotherapies for cancer and autoimmunity. Research Interests and Projects: 1. Development of antibody conjugates for targeted, intra-cellular delivery of macromolecular toxins 2. Engineering monoclonal antibodies for improved pharmacokinetic properties 3. Investigation of sources of inter-individual variability in monoclonal antibody pharmacokinetics 4. Investigation of strategies to overcome the "binding site barrier" to antibody distribution in solid tumors 5. Development of improved mathematical models for predicting the disposition and effects of monoclonal antibody drugs 6. Development of new targeting strategies to optimize the safety and efficacy of intraperitoneal chemotherapy of ovarian cancers (CA118213) 7. Development of FcRn inhibitors for treatment of humoral autoimmune diseases (e.g., myasthenia gravis, autoimmune neutropenia) (AI60687) 8. Development of new strategies to treat immune thrombocytopenic purpura (HL67347) 9. Investigation of the role of FcRn in the absorption, distribution, and elimination of IgG antibodies 10. Development of antibody-based therapies to treat and prevent infection. Efforts are currently focused on prevention of infection by Treponema denticola (DE023080), S. aureus, and A. baumannii

Research Interest

Director, Center for Protein Therapeutics with research focusing on the utilization of pharmacokinetic and pharmacodynamic analyses and mathematical modeling to guide the discovery and development of new immunotherapies for cancer and autoimmunity. Research Interests and Projects: 1. Development of antibody conjugates for targeted, intra-cellular delivery of macromolecular toxins 2. Engineering monoclonal antibodies for improved pharmacokinetic properties 3. Investigation of sources of inter-individual variability in monoclonal antibody pharmacokinetics 4. Investigation of strategies to overcome the "binding site barrier" to antibody distribution in solid tumors 5. Development of improved mathematical models for predicting the disposition and effects of monoclonal antibody drugs 6. Development of new targeting strategies to optimize the safety and efficacy of intraperitoneal chemotherapy of ovarian cancers (CA118213) 7. Development of FcRn inhibitors for treatment of humoral autoimmune diseases (e.g., myasthenia gravis, autoimmune neutropenia) (AI60687) 8. Development of new strategies to treat immune thrombocytopenic purpura (HL67347) 9. Investigation of the role of FcRn in the absorption, distribution, and elimination of IgG antibodies 10. Development of antibody-based therapies to treat and prevent infection. Efforts are currently focused on prevention of infection by Treponema denticola (DE023080), S. aureus, and A. baumannii